Bio Techne : Corporate Presentation - January 2023

Where Science

Intersects

Innovation™

Bio-Techne Corporate Presentation | January 2023

Confidential. © 2023 Bio-Techne®. All rights reserved. | 1

Safe Harbor C A U T I O N A R Y S T A T E M E N T S

S A F E H A R B O R

This presentation contains "forward-looking statements" within the meaning of the federal securities laws. Except for historical information contained herein, the statements in this presentation are forward- looking and made pursuant to the safe harbor provisions of the Private Securities

Litigation Reform Act of 1995. Forward-

looking statements made herein relate to, among other things, future sales, earnings, return on equity, cost savings, process improvements, free cash flow, share

repurchases, capital expenditures,

acquisitions, benefits of investments and partnerships, business strategies, the potential impact of COVID-19 on our operations or financial results and other matters. Such statements can be identified

by words such as: "expected,"

"expects," "expect," "forecast," "would," "estimate," "will," or similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our

business, future plans and strategies,

projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks

and changes in circumstances that are difficult

to predict and many of which are outside of our control. Actual results could differ materially from those stated or implied in the forward-looking statements. For a list of factors, risks and uncertainties which could

make our actual results differ from expected

results, please see our latest Annual Report

on Form 10-K. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, as a result of new information, future developments or otherwise. This presentation also contains non-GAAP financial information. Management uses this information in its

internal analysis of results and believes this

information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period

comparisons. For definitions of applicable

non-GAAP financial measures and reconciliations of non-GAAP financial information to GAAP financial information, see the Reconciliations of GAAP to Non- GAAP Financial Measures included in the

Company's financial reports on Forms 10-Q

and 10-K and related press releases.

Confidential. © 2023 Bio-Techne®. All rights reserved. | 2

Overview

Confidential. © 2023 Bio-Techne®. All rights reserved. | 3

Business Overview

President & CEO

Chuck Kummeth

Headquarters

Minneapolis, MN

Number of Employees

~3,000

Worldwide Presence

34 Locations

FY2022 Revenues

$1.1B

NASDAQ

TECH

Market Cap

~$13B

Instruments	Services
11%	6% Royalties
	2%

Consumables

81%

Product Portfolio

Proteins

Immunoassays

Spatial

Biology

Liquid

Biopsy

Antibodies

Proteomic

Analytical

Instruments

Molecular Diagnostics

Diagnostic

Reagents &

Controls

Confidential. © 2023 Bio-Techne®. All rights reserved. | 4

FY22 Revenue by

Customer Type & Geography

Distributors
15%				Asia
OEM				17%
48%	$1.1B	59%	EMEA
15%
Pharma/		Americas
	Biotech
Academia				24%
22%

O V E R V I E W

Confidential. © 2023 Bio-Techne®. All rights reserved. | 5